• Video: Which Patients with Crohn’s Disease Need a CT Scan?

Video: Which Patients with Crohn’s Disease Need a CT Scan?

Researchers have developed a system to identify patients with Crohn’s disease who do not require computed tomography (CT) evaluation, described by Shail M. Govani et al  in the October issue of Clinical Gastroenterology and Hepatology. The system uses laboratory test results to avoid CT analysis, and thereby unnecessary exposure to radiation and increased cancer risk. People who come to the emergency department with

Read more

In Treating Crohn’s Disease, Earlier is Better

Patients receiving medical therapies when they have more complicated stages of Crohn’s disease (CD) are more likely to require surgery, researchers report in the March issue of Clinical Gastroenterology and Hepatology. The disease is most-effectively treated by drugs at its early, inflammatory stages. Patients have a 40%–71% risk for requiring

Read more

Are Mitochondria Involved in Ulcerative Colitis?

Changes in mitochondrial DNA that increase levels of ATP in the intestinal mucosa protect mice from colitis, according to the November issue of Gastroenterology. Strategies to increase mitochondrial ATP production by intestinal epithelial cells might therefore be developed to treat patients with ulcerative colitis (UC). Characteristics of UC include reduced levels

Read more

Does Thiopurine Therapy Increase Cancer Risk?

Patients with ulcerative colitis (UC) have a 4-fold increase in risk of lymphoma during treatment with thiopurines, compared to UC patients who have not been treated with these drugs, according to a nationwide cohort study in the November issue of Gastroenterology. The risk increases gradually with successive years of therapy,

Read more
  • Cannabis for Crohn’s Disease?

Cannabis for Crohn’s Disease?

Eight weeks of therapy with Δ9-tetrahydrocannabinol (THC)-rich cannabis reduced symptoms in patients with active Crohn’s disease, according to a controlled trial published in the October issue of Clinical Gastroenterology and Hepatology. However, these effects were only temporary. The marijuana plant Cannabis sativa has been used for centuries to treat a

Read more

Are All Patients With IBD at Increased Risk for Colorectal Cancer?

Although inflammatory bowel disease (IBD) increases risk for colorectal cancer (CRC), the risk is only substantial among patients with long-term, extensive colitis. Furthermore, CRC risk is reduced by thiopurine therapy, according to the July issue of Gastroenterology. Laurent Beaugerie et al. collected data from 19,486 patients with IBD (60% with

Read more

What are the Effects of IBD Therapy During Pregnancy?

In pregnant women treated for inflammatory bowel diseases (IBD),  infliximab and adalimumab, but not certolizumab, cross the placenta and are detected in infants up to 6 months after birth, according to the March issue of Clinical Gastroenterology and Hepatology (CGH). However, they do not appear to cause birth defects, and women

Read more

Who Will Develop Pouchitis After Ileal Pouch–Anal Anastomosis?

Serum markers can be used to identify patients with ulcerative colitis most likely to have inflammatory complications after ileal pouch–anal anastomosis (IPAA), according to the May issue of Clinical Gastroenterology and Hepatology. More than 20% of individuals with ulcerative colitis eventually need surgery for this disease. Patients with fulminant or

Read more

Is Medicine or Surgery the Best Treatment for Crohn’s Disease?

For patients with Crohn’s disease and intra-abdominal abscesses, nonsurgical and surgical management strategies result in similar rates of abscess recurrence and complications, according to the April issue of Clinical Gastroenterology and Hepatology. Crohn’s disease can progress from inflammation and ulceration to bowel damage that includes formation of abscesses, phlegmon, and

Read more

Can Patients With Crohn’s Disease Ever Stop Taking Infliximab?

Half of patients with Crohn’s disease treated with infliximab experience a relapse within the first year after they stop taking the drug, according to a study published in the January issue of Gastroenterology. Drugs such as infliximab inhibit the inflammatory cytokine tumor necrosis factor (TNF) and are effective in reducing

Read more